Recrudescence of *Helicobacter pylori* after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting

H X Xia, H J Windle, D G Marshall, C J Smyth, C T Keane, C A O'Morain

Abstract

The aim of this study was to find out if reinfection or recrudescence accounted for the recurrence of *Helicobacter pylori* infections after apparent eradication of the bacterium. Three hundred and twenty patients were treated with colloidal bismuth subcitrate (120 mg four times daily for four weeks), metronidazole and tetracycline (400 mg and 500 mg, respectively, thrice daily for the first week). *H. pylori* was eradicated four weeks after the end of treatment as assessed by the rapid urease test, histological examination, Gram staining, and culture. However, the infection recurred in 29 (9.1%) of the patients one year after apparent eradication. Pre and posteradication isolates from five patients were available. DNA was extracted and used for restriction endonuclease analysis with *Hind* III and *Hae* III, and for polymerase chain reaction (PCR) based randomly amplified polymorphic DNA fingerprinting with a combination of two 10 nucleotide primers. Sodium dodecyl sulphate polyacrylamide gel electrophoretic analysis was performed also. Randomly amplified polymorphic DNA fingerprinting was unique in that it yielded highly discriminatory fingerprints, which showed that the pretreatment and recurrent isolates obtained from each of the five patients were indistinguishable from one another. This shows that recurrence of *H. pylori* infection is probably caused by recrudescence and that the discriminatory power of randomly amplified polymorphic DNA fingerprinting is a practicable and discriminatory typing scheme for *H. pylori*.

(Gut 1995; 37: 30-34)

Keywords: *Helicobacter pylori*, DNA fingerprinting, recrudescence.

Eradication of *Helicobacter pylori* cures duodenal ulcer¹⁻³ and ulcer complications.^{4,5} An eradication rate of 84.3% is obtained with colloidal bismuth subcitrate (120 mg four times daily for four weeks), metronidazole and tetracycline (400 mg and 500 mg thrice daily for the first week, respectively).⁶ However, recurrence of the infection after apparent eradication has been reported and is

associated with the ulcer relapse.^{1,3,7-9} Recent studies have shown that recurrence of *H. pylori* is dependent on the efficacy of the treatment regimen. The more effective the treatment, the lower the recurrence rate.^{9,10a} This study was conducted to find out if recurrence of *H. pylori* was caused by reinfection or recrudescence by molecular characterisation of the pretreatment and recurrent isolates from patients, who had been treated with the triple therapy, using three fingerprinting techniques. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of whole cell proteins, restriction endonuclease analysis (REA) of genomic DNA and polymerase chain reaction (PCR) based random amplified polymorphic DNA (RAPD) fingerprinting technique were used in this analysis.

Methods

Clinical details of the patients and *H. pylori* isolates

Three hundred and twenty Irish patients with confirmed duodenal ulcer were treated with a triple therapy, which included colloidal bismuth subcitrate (120 mg four times daily for four weeks), metronidazole and tetracycline (400 mg and 500 mg, respectively, thrice daily for the first week). *H. pylori* was eradicated four weeks after the end of treatment as assessed by the rapid urease test (CLO test, Delta West, Perth, Western Australia), histological examination, Gram staining, and culture (all showed negative results for *H. pylori*). Details of specimen preparation and classification criteria for gastritis used in this study have been described elsewhere.¹ Each of the patients had a routine endoscopy one year after apparent eradication of the bacterium, or sooner if symptoms recurred. Recurrence of *H. pylori* infection was defined as any one (or more) of the four tests described for *H. pylori* being positive. Recurrence of *H. pylori* infection was apparent in 29 (9.1%) of the patients. Posteradication *H. pylori* was isolated from antral biopsy specimens of 23 of these patients. Both pretreatment and recurrent isolates were, however, successfully recovered from only five of these patients; two isolates were obtained from each of four patients, and three isolates from one patient. The Table gives the clinical details of these five patients and the 11 isolates.

Department of Clinical Microbiology, St James's Hospital
H X Xia
C T Keane

Departments of Clinical Medicine
H J Windle

and Microbiology
D G Marshall
C J Smyth

and Department of Gastroenterology, Meath/Adelaide Hospitals
C A O'Morain

Trinity College, Dublin, Ireland

Correspondence to: Dr H Xia, Department of Clinical Microbiology, CPL, St James's Hospital, Dublin 8, Ireland.

Accepted for publication 10 November 1994

Clinical details of the patients before *H pylori* was apparently eradicated with colloidal bismuth subcitrate, metronidazole, and tetracycline (triple therapy) and after the infection recurred during a period of follow up

Patient	Treatment status	Age (y)	Sex	Endoscopic diagnosis	Histological findings	Isolate	Follow up (months)
A	Before After	32	Female	DU NUD	Mo+Ac Mo+Ac	A1 A2	7
B	Before After	60	Female	DU DU	Mi+Ac Mi	B1 B2	8
C	Before After	19	Female	DU NUD	Mo+Ac Mo+Ac	C1 C2	10
D	Before After	31	Male	DU DU	Ma+Ac Mi+Ac	D1 D2a	12
E	Before After	66	Female	DU NUD	Ma+Ac Mo+Ac	D2b E1 E2	22*

**H pylori* was positive 13 months after eradication, but only cultured nine months later; DU, duodenal ulcer; NUD, non-ulcer dyspepsia; Mi+Ac, mild and active antral gastritis; Mo+Ac, moderate and active antral gastritis; Ma+Ac, considerable and active antral gastritis.

Preparation of bacterial cells

Pre and posteradication isolates of *H pylori* from patients A, B, C were used for REA, and from patients A, B, C, and D for SDS-PAGE. All the isolates were used for RAPD. A reference *H pylori* strain NCTC 11638 was included in all but one of the experiments. Each isolate was recovered from tryptone soya broth containing glycerol (20%, v/v) and horse serum (10%, v/v) and stored at -70°C . The recovered isolates were then subcultured either on chocolate agar plates for three to five days in a microaerophilic atmosphere at 37°C , or in a tissue culture flask containing brain heart infusion broth (20 ml) containing horse serum (5%, v/v) and yeast extract (0.25%, w/v) for 24–48 hours, exactly as described previously.¹⁰

SDS-PAGE

Agar grown bacteria were harvested with phosphate buffered saline (PBS, pH 7.3) and washed twice in this buffer prior to measuring the protein content of each strain by the method of Markwell *et al.*¹¹ Bacterial protein (10 μg) in PBS was precipitated by the addition of five volumes of ice cold acetone, followed by incubation at -20°C for 30 minutes. After washing the precipitate once with acetone, the pellet was resuspended in 10 μl sample buffer. The mixture was boiled for four minutes prior to electrophoresis. SDS-PAGE was performed as previously described,¹² using 12.5% acrylamide resolving gels. Molecular weight markers were SDS-PAGE broad range standards (Bio-Rad, CA, USA).

Extraction of genomic DNA

Bacterial cells on chocolate agar (two plates), or liquid medium (15 ml) were washed with PBS (pH 7.3) and 25 mM TRIS-HCl buffer (pH 8.0) containing 10 mM EDTA. The suspension was transferred into an Eppendorf tube and washed twice with TRIS-HCl buffer. DNA was extracted by a phenol/chloroform method similar to the method previously described.¹³ Briefly, the pellet of cells was resuspended in 0.5 ml lysis buffer (25 mM TRIS-HCl (pH 8.0), 50 mM glucose, 10 mM EDTA, lysozyme (30 mg/ml)) and incubated at room temperature for 15 minutes. The suspension was treated with SDS, RNase A,

and then pronase. DNA was extracted with phenol/chloroform/isoamyl alcohol, precipitated by sodium acetate and cold absolute alcohol, and washed with ice cold alcohol (70%, v/v). The pellet of DNA was finally resuspended in 10 mM TRIS-HCl buffer (pH 7.5) containing 1 mM EDTA. DNA content and purity was determined by measuring the absorbance at 260 nm and 280 nm using a spectrophotometer (Hitachi, U-2000, Japan). All reagents used for DNA extraction were obtained from Sigma Chemical, MO, USA. DNA templates for RAPD were prepared also by the boiling method exactly as described by Mazurier *et al.*¹⁴

REA and RAPD

Restriction endonuclease digestion of *H pylori* genomic DNA with *Hind* III or *Hae* III was carried out according to the manufacturer's instructions (Boehringer Mannheim, GmbH, Germany).

RAPD fingerprinting was carried out in a final volume of 25 μl containing 3 mM MgCl_2 , 20 pmol of each primer, 2.5 U of Taq DNA polymerase (Promega, WI, USA), 250 μM each of dCTP, dGTP, dATP, dTTP (Boehringer Mannheim) in 10 mM TRIS-HCl (pH 8.3) containing 50 mM KCl and Triton X-100 (1%, v/v). The mixture was overlaid with mineral oil and exposed to ultraviolet radiation for 10 minutes. Between 5 and 500 ng DNA template of each isolate obtained by the phenol/chloroform method, or 5 μl cell supernatant fraction prepared by the boiling method was used for PCR. The primers used were a combination of two 10 nucleotide primers, primer 1281 (AACGCGCAAC) and primer 1283 (GCGATCCCCA) obtained from the Molecular Medicine Unit, King's College School of Medicine and Dentistry, London. The synthesis and specificity of these primers has been described previously.^{15,16} A Perkin-Elmer TC480 thermal cycler (Cetus, USA) was used for amplification. The cycling programme was four cycles of (94°C , 5 min; 36°C , 5 min; and 72°C , 5 min), 30 cycles of (94°C , 1 min; 36°C , 1 min; and 72°C , 2 min), and then 72°C for 10 minutes.

Agarose gel electrophoresis

Genomic DNA (20 μl) or digested DNA (20 μl) was mixed with 5 μl loading buffer consisting of 50% (v/v) TBE running buffer (pH 8.0), glycerol (50%, v/v), and bromophenol blue (0.25%, w/v). Loading buffer (5 μl) was added to an aliquot of PCR products and 20 μl of the mixture was electrophoresed. A 0.5% agarose gel was used for genomic DNA, a 0.8% agarose gel for digested DNA, and a 2% agarose gel for PCR products. After electrophoresis in 0.5 $\times$ TBE buffer at 70 V, gels were stained in ethidium bromide (0.5 mg/ml) and photographed under ultraviolet light. *Hind* III digested bacteriophage λ DNA (Sigma) was used as a size marker for genomic DNA in REA; a 100 bp DNA ladder (Gibco, BRL) was used for PCR products.

Figure 1: SDS-PAGE protein profiles of reference strain NCTC 11638 (R) and paired clinical isolates from patients A, B, C, and D. The molecular weight marker proteins (M) were myosin ($M_r=200\,000$), β -galactosidase ($M_r=116\,250$), phosphorylase b ($M_r=97\,400$), bovine serum albumin ($M_r=66\,200$), ovalbumen ($M_r=45\,000$), carbonic anhydrase ($M_r=31\,000$), soya bean trypsin inhibitor ($M_r=21\,500$), and lysozyme ($M_r=14\,400$).

Results

SDS-PAGE

Patterns of whole cell protein extracts obtained by SDS-PAGE showed 30–40 bands for each isolate with molecular weights of 20 to 120 K. The six major bands of 27, 30, 46, 54, 57, and 64 K were present in the protein profiles of all of the isolates. Although the protein patterns of pretreatment and recurrent isolates from individual patients were very similar it was still possible to distinguish between the profiles of paired isolates from different patients because of minor variations in the expression of some protein constituents, chiefly in the 100–200 K and the 30–37 K regions (Fig 1).

REA

Electrophoresis of undigested genomic DNA showed that the reference strain NCTC 11638 harboured one plasmid of 9.0 kb. Isolates A1 and A2 both harboured two plasmids of the same size (9.6 kb and 5.4 kb). C1 and C2 both had two plasmids of the same size also (15 kb

Figure 2: Restriction endonuclease analysis. Agarose gel electrophoretic patterns of undigested genomic DNA (left hand side) and Hind III digested DNA (right hand side) restriction fragments of strain NCTC 11638 (R) and paired isolates from patients A, B, and C. The molecular size markers (M) are fragments from Hind III digested bacteriophage λ DNA.

and 8.2 kb). Isolates B1 and B2 shared one plasmid of 25 kb (Fig 2). Hind III digested DNA from all of the three pairs of isolates (Figs 2 and 3), but Hae III only cut DNA from isolate B (Fig 3). Hind III digest profiles of genomic DNA from isolates C1 and C2 were very similar (Fig 3), whereas the REA profiles of isolates A1 and A2 and of isolates B1 and B2 showed considerable similarity, although a number of band differences were apparent in the 8–10 kb regions of the isolates A1/A2 and in the 6–6.5 kb region of the paired isolates B1/B2 (Figs 2 and 3). There were distinct differences in the digest profiles of DNA between the clinical isolates, and between the clinical isolates and the reference strain.

RAPD

RAPD fingerprinting with a combination of the two 10 nucleotide primers yielded 10 to 20 main bands on the agarose gels. The profiles of the PCR products from the DNA of the paired isolates A1/A2, B1/B2, C1/C2, D1–D2a/D2b, and E1/E2 were clearly indistinguishable from one another when the DNA was prepared by the phenol/chloroform method (Fig 4, data for E1/E2 not shown). However, isolates from patients A, B, C, D, E, and the reference strain yielded considerably different RAPD profiles. The DNA templates prepared by the boiling method also yielded highly discriminatory fingerprints, although slightly less PCR products were obtained when compared with the DNA templates prepared by the phenol/chloroform method (Fig 5).

Discussion

In this study we have shown that the DNA fingerprints of five paired pretreatment and recurrent *H. pylori* isolates from five patients were identical. This was accomplished by the application of RAPD fingerprinting to confirm the identity of the paired isolates. Our findings clearly showed that recrudescence, rather than reinfection, accounted for the recurrence of

Figure 3: Restriction endonuclease analysis. Agarose gel electrophoretic patterns of Hind III digested (left hand side) and Hae III digested (right hand side) DNA restriction fragments of paired isolates of *H. pylori* from patients A, B, and C. The molecular size markers (M) are fragments from Hind III digested bacteriophage λ DNA.

Figure 4: Representative agarose gel electrophoretic patterns of RAPD products of genomic DNA of reference strain NCTC 11638 (R) and paired isolates from patients A, B, C, and D. M=size markers, 100 base pair ladder.

H pylori infection after apparent eradication with antimicrobial therapy in all five cases examined. Both SDS-PAGE and REA had less discriminatory power when compared with RAPD. To our knowledge, this is the first reported application of RAPD to confirm the identity of paired clinical isolates of *H pylori* obtained from subjects in whom recurrence of the infection occurred after apparent eradication of the organism. The discriminatory power of RAPD fingerprinting represents a potentially practicable and discriminatory typing scheme for *H pylori*.

Several fingerprinting techniques have been used for typing *H pylori*. The numerical analysis of SDS-PAGE protein patterns¹⁷ and restriction endonuclease DNA analysis^{13 18 19} are sensitive and useful for defining the similarities between isolates. Both techniques are time consuming, however, and scanning the numerous bands for each pattern requires expensive equipment. Ribotyping with *Hae* III and *Hind* III provides a reliable, reproducible, and discriminatory basis for distinguishing one strain from another.^{20 21} However, the DNA of 25% of strains is not cut by *Hae* III. *Hind* III ribotyping patterns are conserved, with several groups of *H pylori* often having the same ribopattern.²¹ In this study, DNA from two of three pairs of strains were not cut by *Hae* III.

PCR based RAPD fingerprinting is a recently developed technique.²² Its simplicity, versatility, and economy make it an ideal means of genetically fingerprinting isolates. This technique has been used successfully to distinguish clinical isolates of *H pylori*¹⁵ and a combination of the two 10 nucleotide primers used in this study, 1281 and 1283, was found previously to be very suitable for discriminating Irish isolates.¹⁶ In this study, SDS-PAGE protein profiling and restriction endonuclease DNA fingerprinting analysis were applied also, but the electrophoretic patterns were not as easy to compare. In our hands REA yielded less informative data than RAPD. It is interesting to note that other workers using REA found both minor and major band differences between many paired isolates.¹³ However, the reasons for the reproducible differences we saw when using REA are not clear. In any event,

RAPD yielded very satisfactory fingerprinting profiles. Ready discrimination between the isolates was possible even when the DNA template was prepared by a boiling method.

Recurrence rates of *H pylori* infection from 0–50% have been reported for patients who are followed up for periods of one to seven years.^{1–3 7–9} Recurrence rates differ depending on the treatment regimen.⁹ We have shown that of 125 one year follow up patients, in whom *H pylori* had been eradicated, the infection recurred in 47.1% of the patients treated with monotherapy, in 31.8% of those treated with dual therapy, and in 10.9% of those treated with triple therapy.^{10a} Therefore, the more effective treatment is associated with a low recurrence rate. Furthermore, in a clinical study of 304 patients, who were followed up tri-monthly for 60 months,⁹ 19 (6.3%) had *H pylori* recurrence as assessed using a single test, the ¹⁴C urea breath test; 17 of which (89.5% of the 19 recurrences) occurred within six months after treatment (11 within three months). None of the patients were 'reinfected' with the organism after 24 months. A higher recurrence rate (9.1%) was seen in this study, using four techniques to detect *H pylori*. Although the recurrent isolates from the five patients were cultured between seven and 22 months after the first isolation in this study, the infection might have recurred much earlier as two of these patients did not present until symptoms returned and the other three attended for a one year follow up endoscopy without symptoms.

Previous studies, using SDS-PAGE and REA, have shown that strains of *H pylori* from different patients are genetically distinct from each other, and that the same strains persist in patients for at least two years, even after the patients received antimicrobial therapy.^{17 18} Langenberg *et al* have also shown that a recurrent strain of *H pylori*, after apparently successful eradication is genetically identical to the pretreatment strain using REA.¹⁸ In our study, the five patients examined were from 29 patients in whom *H pylori* infection recurred after apparently successful eradication. They were selected only on the basis that both their pre and posteradication isolates were available. Thus, these five patients were possibly representative of all the 29 patients. DNA

Figure 5: Representative agarose gel electrophoretic patterns of RAPD products of genomic DNA of *H pylori* prepared by the phenol/chloroform (left hand side) and boiling (right hand side) methods. R=reference strain NCTC 11638 M=size markers, 100 base pair ladder.

fingerprints of RAPD showed that the recurrent *H. pylori* strains in each of the five patients were identical to the original strains, which suggests that the nature of *H. pylori* recurrence after eradication is recrudescence rather than reinfection.

The means by which recrudescence arises is equivocal at present. Two possibilities are either incomplete eradication of the bacterium by drug treatment or incomplete elimination of the bacterium from the host. Support for these explanations is provided by several studies. *H. pylori* can live in human gastric pits, where it might avoid the bactericidal activity of antimicrobial agents and recolonise after treatment has finished.²³ *H. pylori* can also change its morphology from typical helical to a coccoidal form under the hostile conditions found in the gastric environment and can revert to its original shape under favourable conditions.²⁴ Incomplete elimination would most probably occur if the organism inhabited a reservoir other than the stomach. This possibility is strengthened by the findings that *H. pylori* has been found in saliva,²⁵ dental plaque,²⁶ and faeces.²⁷⁻²⁸ In addition, as it has been found that members within the same family may harbour identical strains,²⁰⁻²⁹ there is also a possibility that these patients might have been reinfected with strains from the same reservoir as the pretreatment strains. Other studies, however, have shown that most family members are infected with different strains.¹³⁻¹⁹

In conclusion, the findings in this study using a highly discriminatory molecular fingerprinting technique, RAPD, show that the recurrence of *H. pylori* infection after apparently successful eradication is caused by recrudescence rather than reinfection. Thus, the definition of eradication of *H. pylori* currently used may need to be revised. It is suggested that eradication should be defined as the inability to detect *H. pylori* at least six months after cessation of antimicrobial therapy.⁹ Furthermore, as *H. pylori* urease activity may be undetectable in small numbers of organisms³⁰ or when expression of the enzyme is inhibited by antimicrobial agents or proton pump inhibitors for a period of time after treatment,³¹ tests that are based on urease activity should be complemented by at least one other technique, such as Gram staining, culture, histological examination or serology when determining the extent of eradication or recurrence of *H. pylori* infection.

The preliminary results of this study were orally presented to the British Society of Gastroenterology in March 1994. (*Gut* 1994; 35 (suppl 2): S3.) The authors thank the medical and endoscopy staff and research nurses of Meath/Adelaide Hospitals and Professor Jinkun Zhang of Union Hospital, Wuhan, Peoples Republic of China, for their help, cooperation, and support.

- 1 Patchett S, Beattie S, Leen E, Keane C, O'Morain C. Helicobacter pylori and duodenal ulcer recurrence. *Am J Gastroenterol* 1992; 87: 24-7.
- 2 Rauws EA, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. *Lancet* 1990; 335: 1233-5.
- 3 Forbes GM, Glaser ME, Cullen DJE, Warren JR, Christiansen KJ, Marshall BJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. *Lancet* 1994; 343: 258-60.
- 4 Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rebleeding in peptic ulcer disease. *Scand J Gastroenterol* 1993; 28: 939-42.

- 5 Labenz J, Borsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. *Digestion* 1994; 55: 19-23.
- 6 Xia HX, Daw MA, Sant S, Beattie S, Keane CT, O'Morain CA. Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. *European Journal of Gastroenterology and Hepatology* 1993; 5: 141-4.
- 7 Borody T, Andrews P, Mancuso N, Jankiewicz E, Brandl S. Helicobacter pylori reinfection 4 years post-treatment. *Lancet* 1992; 339: 1295.
- 8 Labenz J, Gyenes E, Ruhl GH, Borsch G. Helicobacter pylori re-infection and clinical course of peptic ulcer disease in the first year post-amoxicillin/omeprazole treatment. *European Journal of Gastroenterology and Hepatology* 1992; 4: 493-6.
- 9 Bell GD, Powell KU, Burrige SM, Harrison G, Rameh B, Weil J, et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection; implications for treatment of patients with duodenal ulcer disease. *Q J Med* 1993; 86: 375-82.
- 10a Xia HX, Gilvarry J, Sweeney EC, Beattie S, Hamilton H, Keane CT, et al. Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. *Am J Gastroenterol* (in press).
- 10 Xia HX, English L, Keane CT, O'Morain CA. Enhanced cultivation of Helicobacter pylori in liquid media. *J Clin Pathol* 1993; 46: 750-3.
- 11 Markwell MAK, Haas SM, Bieberg LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. *Anal Biochem* 1978; 87: 206-10.
- 12 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 1970; 227: 680-5.
- 13 Majewski SI, Goodwin CS. Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable genomic variation. *J Infect Dis* 1988; 157: 465-71.
- 14 Mazurier S, van de Giessen A, Heuvelman K, Wernars K. RAPD analysis of Campylobacter isolates: DNA fingerprinting without the need to purify DNA. *Lett Appl Microbiol* 1992; 14: 260-2.
- 15 Akopyanz N, Bukanov NO, Westblom TU, Kresovich S, Berg DE. DNA diversity among clinical isolates of Helicobacter pylori detected by PCR based RAPD fingerprinting. *Nucleic Acids Res* 1992; 20: 5137-42.
- 16 Marshall DG, Chua A, Keeling PWN, Sullivan DJ, Coleman D, Smyth CJ. Molecular epidemiology of Helicobacter pylori isolates from gastric biopsies. *Ir J Med Sci* 1993; 162: 514.
- 17 Costas M, Owen RJ, Bickley J, Morgan DR. Molecular techniques for studying the epidemiology of infection by Helicobacter pylori. *Scand J Gastroenterol* 1991; 26 (suppl 181): 20-32.
- 18 Langenberg W, Rauws EAJ, Widjojokusumo A, Tytgat GNJ, Zanen HC. Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. *J Clin Microbiol* 1986; 24: 414-7.
- 19 Simor AE, Shames B, Drumm B, Sherman P, Low DE, Penner JL. Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. *J Clin Microbiol* 1990; 28: 83-6.
- 20 Tee W, Lambert J, Smallwood R, Schembri M, Ross BC, Dwyer B. Ribotyping of Helicobacter pylori from clinical specimens. *J Clin Microbiol* 1992; 30: 1562-7.
- 21 Owen RJ. Microbiological aspects of Helicobacter pylori infection. *Communicable Disease Report Review* 1993; 3: R51-6.
- 22 Welsh J, McClelland M. Fingerprinting genomes using PCR with arbitrary primers. *Nucleic Acids Res* 1990; 18: 7213-8.
- 23 Goodwin, Armstrong JA, Marshall BJ. Campylobacter pylori, gastritis and peptic ulcer. *J Clin Pathol* 1986; 39: 353-65.
- 24 Mai U, Geis G, Leying H, Ruhl G, Opferkuch W. Dimorphism of Campylobacter pylori. In: Megraud F, Lamouliatte H, eds. *Gastrointestinal pathology and Campylobacter pylori*. Amsterdam: Elsevier Science, 1989: 29-33.
- 25 Husson MO, Gottrand F, Turck D, Leclerc H. Detection of Helicobacter pylori in saliva using a monoclonal antibody. *Int J Med Microbiol Virol Parasitol Infect Dis* 1993; 279: 466-471.
- 26 Takagi A, Ohta U, Kohda K, Kobayashi H, Shirari T, Harasawa S, et al. Detection of Helicobacter pylori DNA in dental plaque by PCR [Abstract]. *Am J Gastroenterol* 1994; 89: 1298.
- 27 Thomas JE, Gibson GR, Darboe MK, Dale A, Weaver LT. Isolation of Helicobacter pylori from human faeces. *Lancet* 1992; 340: 1194-5.
- 28 Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori in faeces from patients in the UK - confirmation of culture identity by PCR [Abstract]. *Gut* 1994; 35 (suppl 2): S3.
- 29 Rauws EAJ, Langenberg W, Oudbier J, Mulder CJJ, Tytgat GNJ. Familial clustering of peptic ulcer disease colonized with C. pylori of the same DNA composition. *Gastroenterology* 1989; 96: A409.
- 30 Xia HX, Keane CT, O'Morain CA. Pre-formed urease activity of Helicobacter pylori as determined by a viable cell count technique - clinical implications. *J Med Microbiol* 1994; 40: 435-9.
- 31 Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. *Antimicrob Agents Chemother* 1993; 37: 769-74.